 |
JOURNAL TOOLS |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Reprints |
| Permissions |
| Share |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEWS
Minerva Pneumologica 2014 June;53(2):81-3
Copyright © 2014 EDIZIONI MINERVA MEDICA
language: English
N-acetylcysteine and idiopathic pulmonary fibrosis
Rindone E. 1, Rosset L. 2, Carnuccio C. 3
1 Department of Clinical Biological Sciences, Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy; 2 Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy; 3 Casa di Cura Villa Serena, Piossasco, Turin, Italy
Despite there are a lot of ongoing trials studying drugs for the idiopathic pulmunary fibrosis (IPF) still there is not a cure. By the moment that N-acetylcysteine (NAC)-based therapy is commonly used to treat IPF patients and the results of a 2012 study went in this direction, and finally the PANTHER-IPF study results, regarding the NAC monotherapy arm, are about to be published, we decided to collect and analyze all the data that we could find on PubMed and make a sum of them all. At the end of this work we can strongly recommend further investigation on the NAC monotherapy in IPF patients since different studies give us good results on this direction.